In 2023, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved 1,829 evaluation applications for biopharmaceuticals that were subjected to technical reviews. The approvals included 891 therapeutic Investigational New Drug (IND) applications, 59 prophylactic IND applications, and 147 New Drug Applications (NDA).
An approved IND application is the prerequisite for a drug product to enter its clinical trial phase, and a drug can only enter the market for general use after its NDA application is approved by the regulatory body.
Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application
Adjust the presentation of the statistic and data points.
Share the statistic on social media channels or embed the statistic in your
website using "Embed Code", where available.
Cite this statistic and select one of the following formats: APA, Chicago, Harvard, MLA & Bluebook.
Print the statistic including description and metadata.
Chart type
Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application
Share this statistic
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Learn more about how Statista can support your business.
National Medical Products Administration. (February 4, 2024). Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application [Graph]. In Statista. Retrieved February 20, 2025, from https://www.statista.com/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. "Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application." Chart. February 4, 2024. Statista. Accessed February 20, 2025. https://www.statista.com/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. (2024). Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application. Statista. Statista Inc.. Accessed: February 20, 2025. https://www.statista.com/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. "Number of Approved Evaluation Applications for Biopharmaceuticals Subjected to Technical Reviews in China in 2023, by Type of Application." Statista, Statista Inc., 4 Feb 2024, https://www.statista.com/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration, Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application Statista, https://www.statista.com/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/ (last visited February 20, 2025)
Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2023, by type of application [Graph], National Medical Products Administration, February 4, 2024. [Online]. Available: https://www.statista.com/statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.